Pre-treatment with Enpatoran (M5049; oral gavage; 1 mg/kg) before R848 (intraperitoneal injection of 25 µg) dose-dependently inhibits the production of IL-6 and IFN-α in mice.
Enpatoran (M5049) exhibits high oral bioavailability (mouse 100%, rat 87%, dog 84%) following oral administration (mouse, rat and dog 1.0 mg/kg).
Enpatoran exhibits moderate half-lives (mouse 1.4, rat 5.0 and dog 13 h) due to high plasma clearance (1.4, 1.2 and 0.59 L/h/kg, respectively) combined with large volumes of distribution (2.7, 8.7 and 5.7 L/kg, respectively) following intravenous administration (mouse, rat and dog 1.0 mg/kg).
Animal Model: |
Female C57BL/6 mice |
Dosage: |
0.1 mg/kg and 1 mg/kg |
Administration: |
Oral gavage; administered 1 hour prior to R848 challenge |
Result: |
The TLR7/8 agonist R848 stimulated both IFN-α and IL-6 production in mice.
Enpatoran decreased IFN-α and IL-6 production stimulated by R848.
|
Animal Model: |
Female CD1 mice, Female Wistar rats, Female beagle dogs |
Dosage: |
1 mg/kg (Pharmacokinetic Analysis) |
Administration: |
Intravenous (i.v.) or oral gavage |
Result: |
T1/2s of 1.4, 5.0 and 13 h for mice, rats and dogs, respectively. |